Recombinant rabies vaccine - Beijing Luzhu Biotechnology
Latest Information Update: 02 Apr 2023
At a glance
- Originator Beijing Luzhu Biotechnology
- Class Subunit vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rabies
Most Recent Events
- 13 Mar 2023 Preclinical trials in Rabies (Prevention) in China (Parenteral) Prior to March 2023 (Beijing Luzhu Biotechnology pipeline, March 2023)